Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia

Expert Review of Hematology

Volumn 6, Issue 5, 2013, Pages 547-562

  Sorror, Mohamed L ^a   Appelbaum, Frederick R ^b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; age; allogeneic hematopoietic cell transplantation; chromosome aberrations; comorbidity; risk assessment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; ALKYLATING AGENT; AMSACRINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBON MONOXIDE; CARMUSTINE; CD135 ANTIGEN; CLOFARABINE; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; CD4+ T LYMPHOCYTE; CHARLSON COMORBIDITY INDEX; CHIMERA; CHROMOSOME ABERRATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONSOLIDATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CYTOPENIA; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXTERNAL VALIDITY; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAFT FAILURE; GRAFT REJECTION; HAZARD RATIO; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HISPANIC; HLA MATCHING; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; INFECTION COMPLICATION; INTERMETHOD COMPARISON; KARNOFSKY PERFORMANCE STATUS; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG DIFFUSION CAPACITY; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMAL RESIDUAL DISEASE; MONOCYTIC LEUKEMIA; MORTALITY; MULTIPLE LINEAR REGRESSION ANALYSIS; MYELODYSPLASTIC SYNDROME; NEGRO; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; PATIENT DECISION MAKING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL PERFORMANCE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS; SOCIAL SUPPORT; SUICIDE GENE; SURVIVAL RATE; THERAPY EFFECT; UMBILICAL CORD BLOOD; UNRELATED DONORS; WHOLE BODY RADIATION;

AGE FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; RISK ASSESSMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 84885921285     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.827418     Document Type: Review

References (112)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. SEER Cancer Statistics Review, 1975-2003. Ries LAG, Harkins D, Krapcho M et al. (Eds.). National Cancer Institute, Bethesda, MD (2006).
3. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 27, 2758-2765 (2009).
4. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 106, 1154-1163 (2005).
5. Walter RB, Kantarjian HM, Huang X et al Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center study. J. Clin. Oncol. 28, 1766-1771 (2010).
6. Leith CP, Chir B, Kopecky KJ et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 89, 3323-3329 (1997).
7. Leith CP, Kopecky KJ, Chen I-M et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. a Southwest Oncology Group study. Blood 94, 1086-1099 (1999).
8. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107, 3481-3485 (2006).
9. Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. In: Hematology 2005: American Society of Hemtology Education Program Book. Berliner N, Lee SJ, Linenberger M, Vogelsang GB (Eds.). American Society of Hematology, Washington, DC, 143-150 (2005).
10. Ringdén O, Horowitz MM, Gale RP et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 270, 57-60 (1993).
11. de Witte T, Suciu S, Verhoef G et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98, 2326-2331 (2001).
12. de Lima M, Couriel D, Thall PF et al. Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104, 857-864 (2004).
13. Martino R, Caballero MD, Simón JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100, 2243-2245 (2002).
14. Ho AYL, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood 104, 1616-1623 (2004).
15. Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J. Clin. Oncol. 24, 444-453 (2006).
16. Sandmaier BM, Storb R. Reduced-intensity conditioning followed by hematopoietic cell transplantation for hematologic malignancies. In: Thomas' Hematopoietic Cell Transplantation.Appelbaum FR, Forman SJ, Negrin RS, Blume KG (Eds.). Wiley-Blackwell, Oxford, UK, 1043-1058 (2009).
17. Frassoni F, Labopin M, Gluckman E et al Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time-a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 17, 13-18 (1996).
18. Lim Z, Brand R, Martino R et al Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J. Clin. Oncol. 28, 405-411 (2010).
19. McClune BL, Weisdorf DJ, Pedersen TL et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J. Clin. Oncol. 28, 1878-1887 (2010).
20. Sorror ML, Sandmaier BM, Storer BE et al Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 306, 1874-1883 (2011).
21. Estey E, de Lima M, Tibes R et al Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109, 1395-1400 (2007).
22. Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J. Clin. Epidemiol. 52, 27-37 (1999).
23. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann. Hematol. 78, 315-319 (1999).
24. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol. 16, 1582-1587 (1998).
25. Sorror ML, Maris MB, Storer B et al Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 104, 961-968 (2004).
26. Sorror ML, Maris MB, Storb R et al Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106, 2912-2919 (2005).
27. Sorror ML, Sandmaier BM, Storer BE et al Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 25, 4246-4254 (2007).
28. Lim ZY, Ingram W, Brand R et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant. 45, 633-639 (2010).
29. Mohty M, Labopin M., Basara N. et al Association between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and non-relapse mortality (NRM) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) in first complete remission (CR1). Blood 114(22), 270, #650. 11-20-2009.
30. Pagel JM, Gooley TA, Rajendran J et al Allogeneic hematopoietic cell transplantation after conditioning with-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 114, 5444-5453 (2009).
31. Nemecek ER, Guthrie KA, Sorror ML et al Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 17, 341-350 (2011).
32. Gómez-Nuñez M, Martino R, Caballero MD et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant. 33, 477-482 (2004).
33. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. Macleod CM (Ed.). Columbia University Press, New York, USA, 191-205 (1949).
34. Wong R, Shahjahan M, Wang X et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol. Blood Marrow Transplant. 11, 108-114 (2005).
35. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience. J. Clin. Oncol. 11, 2342-2350 (1993).
36. Dreger P, Brand R, Hansz J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning (Review). Leukemia 17, 841-848 (2003).
37. Sorror M, Storer B, Sandmaier BM et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112, 1992-2001 (2008).
38. Artz AS, Pollyea DA, Kocherginsky M et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 12, 954-964 (2006).
39. Degner LF Sloan JA. Decision making during serious illness: what role do patients really want to play? J. Clin. Epidemiol. 45, 941-950 (1992).
40. Sekeres MA, Stone RM, Zahrieh D et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18, 809-816 (2004).
41. Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J. Clin. Oncol. 15, 2644-2651 (1997).
42. Mielcarek M, Gooley T, Martin PJ et al. Effects of race on survival after stem cell transplantation. Biol. Blood Marrow Transplant. 11, 231-239 (2005).
43. Baker KS, Davies SM, Majhail NS et al. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 15, 1543-1554 (2009).
44. Dejardin O, Bouvier AM, Herbert C et al. Social and geographic disparities in access to reference care site for patients with colorectal cancer in France. Br. J. Cancer 92, 1842-1845 (2005).
45. Abou-Nassar KE, Kim HT, Blossom J et al. The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 18, 708-715 (2012).
46. Rizzo JD, Wingard JR, Tichelli A et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol. Blood Marrow Transplant. 12, 138-151 (2006).
47. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML); analysis of 10 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312-1320 (2001).
48. Cancer and Leukemia Group, Farag SS, Archer KJ et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108, 63-73 (2006).
49. van der Holt B, Breems DA, Berna BH et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br. J. Haematol. 136, 96-105 (2007).
50. Frohling S, Schlenk RF, Kayser S et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108, 3280-3288 (2006).
51. Harousseau J-L, Cahn J-Y, Pignon B et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 90, 2978-2986 (1997).
52. Burnett AK, Goldstone AH, Stevens RM et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 351, 700-708 (1998).
53. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 339, 1649-1656 (1998).
54. Suciu S, Mandelli F, de Witte T et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102, 1232-1240 (2003).
55. Cornelissen JJ, van Putten WL, Verdonck LF et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109, 3658-3666 (2007).
56. Koreth J, Schlenk R, Kopecky KJ et al Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systematic review and metaanalysis of prospective clinical trials. JAMA 301, 2349-2360 (2009).
57. Gyurkocza B, Storb R, Storer BE et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J. Clin. Oncol. 28, 2859-2867 (2010).
58. Sayer HG, Kroger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 31, 1089-1095 (2003).
59. Shimoni A, Hardan I, Shem-Tov N et al Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20, 322-328 (2006).
60. Kurosawa S, Yamaguchi T, Uchida N et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol. Blood Marrow Transplant. 17, 401-411 (2011).
61. Farag SS, Wood LL, Schwartz JE et al. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 25, 599-605 (2011).
62. Perrot A, Luquet I, Pigneux A et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 118, 679-685 (2011).
63. Fang M, Storer B, Estey E et al. Outcome of acute myeloid leukemia patients with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 118, 1490-1494 (2011).
64. Schlenk RF, Dohner K, Krauter J et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909-1918 (2008).
65. Wagner K, Damm F, Thol F et al. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica 96, 681-686 (2011).
66. Bullinger L, Dohner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605-1616 (2004).
67. Valk PJ, Verhaak RG, Beijen MA et al Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004).
68. Wilson CS, Davidson GS, Martin SB et al Gene-expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108, 685-696 (2006).
69. Bacigalupo A, Ballen K, Rizzo D et al Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. 15, 1628-1633 (2009).
70. Khouri IF, Keating M, Körbling M et al Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16, 2817-2824 (1998).
71. Lowsky R, Takahashi T, Liu YP et al Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med. 353, 1321-1331 (2005).
72. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390-3400 (2001).
73. Tauro S, Craddock C, Peggs K et al Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 23, 9387-9393 (2005).
74. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91, 756-763 (1998).
75. Corradini P, Zallio F, Mariotti J et al Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J. Clin. Oncol. 23, 6690-6698 (2005).
76. Schmid C, Schleuning M, Schwerdtfeger R et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108, 1092-1099 (2006).
77. Pagel JM, Lionberger J, Sandhu R. et al Frequency of allogeneic hematopoietic cell transplantation among high-risk AML patients in first complete remission at an academic center. Bio. Blood & Marrow Transplantation. 18(2), S288-S289. 2013.
78. Herr AL, Labopin M, Blaise D et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 21, 129-135 (2007).
79. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23, 5675-5687 (2005).
80. Saure C, Schroeder T, Zohren F et al. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a F LAMS A-based high-dose sequential conditioning regimen. Biol. Blood. Marrow. Transplant. 18, 466-472 (2012).
81. Lubbert M, Bertz H, Ruter B et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 44, 585-588 (2009).
82. Mielcarek M, Storer BE, Sandmaier BM et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol. Blood Marrow Transplant. 13, 1499-1507 (2007).
83. Storb R, Gyurkocza B, Storer BE et al Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 31, 1530-1538 (2013).
84. Ho VT, Kim HT, Aldridge J et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 17, 1196-1204 (2011).
85. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60, 778-783 (1995).
86. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med. 351, 2265-2275 (2004).
87. Wagner JE, Barker JN, Defor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100, 1611-1618 (2002).
88. Ostronoff F, Milano F, Gooley T et al. Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin. Bone Marrow Transplant. 48, 782-786 (2013).
89. Brunstein CG, Barker JN, Weisdorf DJ et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110, 3064-3070 (2007).
90. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood (2013) (Epub ahead of print).
91. Aversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23, 3447-3454 (2005).
92. Luznik L, O'Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641-650 (2008).
93. Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? (Review). Hematology 2012, 230-236 (2012).
94. Nakamae H, Storer BE, Storb R et al. Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biol. Blood Marrow Transplant. 16, 384-394 (2010).
95. Woolfrey A, Klein JP, Haagenson M et al. HLA-C antigen mismatch is associated with worse outome in unrelated donor peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant. 17, 885-892 (2011).
96. Flowers MED, Inamoto Y, Carpenter PA et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 117, 3214-3219 (2011).
97. Kollman C, Howe CWS, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98, 2043-2051 (2001).
98. Panse JP, Heimfeld S, Guthrie KA et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after nonmyeloablative conditioning. Br. J. Haematol. 128, 659-667 (2005).
99. Baron F, Storer B, Maris MB et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 12, 1176-1187 (2006).
100. Richa EM, Kunnavakkam R, Godley LA et al. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy 14, 707-715 (2012).
101. Alousi AM, Le-Rademacher J, Saliba RM et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 121, 2567-2573 (2013).
102. Gratwohl A, Hermans J, Goldman JM et al Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352, 1087-1092 (1998).
103. Gratwohl A, Stern M, Brand R et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115, 4715-4726 (2009).
104. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann. Intern. Med. 144, 407-414 (2006).
105. Petersdorf EW, Malkki M, Gooley TA et al. MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation. Sci. Transl. Med. 4, 144ra101 (2012).
106. Bochud P-Y, Chien JW, Marr KA et al Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N. Engl. J. Med. 359, 1766-1777 (2008).
107. Schwind S, Maharry K, Radmacher MD et al Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 28, 5257-5264 (2010).
108. Walter RB, Gooley TA, Wood BL et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J. Clin. Oncol. 29, 1190-1197 (2011).
109. Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-242 (2008).
110. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724 (1997).
111. Bonini C Bordignon C. Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol. Cell Ther. 39, 273-274 (1997).
112. Warren EH Deeg HJ. Dissecting graft-versus-leukemia from graft-versus-host disease using novel strategies. Tissue Antigens 84, 183-193 (2013).